9/4/2007 11:40:55 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ViaCell, Inc. (Nasdaq:VIAC) announced today it has entered into an agreement under which EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, will provide support related to the clinical development of ViaCyteSM, ViaCell’s investigational product for the cryopreservation and thawing of human oocytes for use during assisted reproductive technology. In addition, EMD Serono has agreed to provide certain quantities of two of its products, Gonal-f® RFF Pen (follitropin alfa injection) and Ovidrel® Prefilled Syringe (choriogonadotropin alfa injection), for the treatment of patients participating in the ViaCyte study. Financial terms were not disclosed.
comments powered by